Publicação

Treatment of Hepatitis C Virus Infection in Kidney Transplant Recipients: Case Report

Ver documento

Detalhes bibliográficos
Resumo:Chronic hepatitis C virus (HCV) infection exists in a large proportion of patients undergoing renal transplantation. Nowadays it is not considered to be an absolute contraindication to transplantation; however, it is associated with an increased risk for the patient and accounts for a shorter half-life of the renal allograft. We present three transplant recipients who displayed serious hepatic dysfunction after renal transplantation due to an HCV infection. In two of these cases, the liver biopsies established the diagnosis of FCH. In the third case, the liver biopsy was compatible with the early stages of FCH. All patients were started on peg-interferon alfa 2-b and ribavirin with subsequent normalization of hepatic function and early complete viral responses.
Autores principais:Caeiro, F
Outros Autores:Baptista, V; Rodrigues, N; Carvalho, D; Aires, I; Remédio, F; Nolasco, F
Assunto:Antivirais Hepatite C Biópsia Interferão Alfa Transplantação de Rim Fígado Proteínas Recombinantes HCC NEF
Ano:2011
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Centro Hospitalar de Lisboa Central, EPE (CHLC)
Idioma:inglês
Origem:Repositório do Centro Hospitalar de Lisboa Central, EPE
Descrição
Resumo:Chronic hepatitis C virus (HCV) infection exists in a large proportion of patients undergoing renal transplantation. Nowadays it is not considered to be an absolute contraindication to transplantation; however, it is associated with an increased risk for the patient and accounts for a shorter half-life of the renal allograft. We present three transplant recipients who displayed serious hepatic dysfunction after renal transplantation due to an HCV infection. In two of these cases, the liver biopsies established the diagnosis of FCH. In the third case, the liver biopsy was compatible with the early stages of FCH. All patients were started on peg-interferon alfa 2-b and ribavirin with subsequent normalization of hepatic function and early complete viral responses.